
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer
Plus, news about Tribune Therapeutics and Leap Therapeutics: Humacyte’s $50M offering: The North Carolina biotech is selling 25 million shares at … Sign up to read this article for free. Get free access to a limited number of articles, plus …